Safety evaluation of hemagglutinating virus of Japan--artificial viral envelope liposomes in nonhuman primates.
We tested, in cynomolgus monkeys, the safety and effectiveness of a hybrid liposome vector, hemagglutinating virus of Japan (HVJ)--artificial viral envelope (AVE) liposomes, for human therapeutic gene transfer in a series of experiments. In a repetitive intramuscular administration study, vehicle control macaques (n = 2), which were treated with HVJ--AVE liposome suspension, received repetitive intramuscular injections of 2 ml of test substance. Human hepatocyte growth factor (HGF) cDNA-inserted expression vector (pUC-SR alpha/HGF) injection animals (n = 2), which were treated with HVJ--AVE liposome suspension containing pUC-SR alpha/HGF, received repetitive intramuscular injection of 2 ml of test substance. General body condition, hematology, blood chemistry, and serum HGF were determined sequentially before treatment and 7, 21, 28, and 29 days after treatment. Elevations in HGF were detected in monkeys injected with pUC-SR alpha/HGF. After this observation period, macaques were killed for autopsy and histological examination. pUC-SR alpha/HGF was detected by polymerase chain reaction (PCR) analysis in the liver, spleen, and at the injection site. In single intravenous administration study, control macaques (n = 4) received a single intravenous injection of 10 ml of physiological saline. Vehicle control animals (n = 5) received a single intravenous injection of 10 ml of HVJ--AVE liposome suspension. DNA-treated animals (n = 7) received a single intravenous injection of 10 ml of HVJ--AVE liposome suspension containing plasmid DNA [pcDNA 3.1(+)]. General body condition, body weight, hematology, blood chemistry, and urine composition were determined sequentially before treatment and 1, 14, 21, and 28 days after treatment. After this observation period, macaques were killed for autopsy and histological examination. pcDNA 3.1(+) was detected by PCR analysis on day 1 in lung, liver, and spleen of all monkeys, in kidney of one of two monkeys, and in heart of one of two monkeys. However, no DNA was detected in any of the tissues examined on days 14, 21, and 28. No virus genomic RNA was detected by reverse transcription (RT)-PCR analysis with HVJ-specific primers. In this series of safety evaluations, the animals tolerated the safety study with no change in body weight or general condition. No hematological changes or alterations in blood chemistry or urine composition was detected. Moreover, no histological changes were observed. This safety evaluation study demonstrates the safety, feasibility, and therapeutic potential of the novel transfection vehicle, HVJ--AVE liposomes, in humans.
Division of Gene Therapy Science, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan.
N
N
Tsuboniwa
R
R
Morishita
T
T
Hirano
J
J
Fujimoto
S
S
Furukawa
M
M
Kikumori
A
A
Okuyama
Y
Y
Kaneda
D000818:Animals; D004247:DNA / Q000378:metabolism; D018076:DNA, Complementary / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D005260:Female; D005822:Genetic Vectors; D017228:Hepatocyte Growth Factor / Q000097:blood / Q000235:genetics; D006801:Humans; D006967:Hypersensitivity; D008081:Liposomes / Q000378:metabolism*; D008099:Liver / Q000378:metabolism; D008252:Macaca fascicularis; D008297:Male; D010957:Plasmids / Q000378:metabolism; D016133:Polymerase Chain Reaction; D012313:RNA / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D018108:Respirovirus / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013154:Spleen / Q000378:metabolism; D013997:Time Factors; D014018:Tissue Distribution; D014162:Transfection
D018076:DNA, Complementary; D008081:Liposomes; D011993:Recombinant Fusion Proteins; D012313:RNA; D017228:Hepatocyte Growth Factor; D004247:DNA